agilon health, inc. Earnings Per Share Disclosure
NOTE 15. Net Income (Loss) Per Common Share | ||
| Year Ended December 31, | |||||||||||||||||
| 2025 | 2024 | 2023 | |||||||||||||||
| Numerator | |||||||||||||||||
| Income (loss) from continuing operations | $ | (405,347) | $ | (250,277) | $ | (195,253) | |||||||||||
| Noncontrolling interests’ share in (earnings) loss from continuing operations | — | (50) | 207 | ||||||||||||||
| Net income (loss) attributable to common stockholders before discontinued operations | (405,347) | (250,327) | (195,046) | ||||||||||||||
| Income (loss) from discontinued operations | 14,000 | (9,824) | (67,550) | ||||||||||||||
| Net income (loss) attributable to common stockholders | $ | (391,347) | $ | (260,151) | $ | (262,596) | |||||||||||
| Denominator | |||||||||||||||||
| Weighted average shares outstanding, basic and diluted | 413,969 | 410,966 | 408,917 | ||||||||||||||
| Net income (loss) per share attributable to common stockholders | |||||||||||||||||
| Net income (loss) per common share from continuing operations, basic and diluted | $ | (0.98) | $ | (0.61) | $ | (0.48) | |||||||||||
| Net income (loss) per common share from discontinued operations, basic and diluted | $ | 0.03 | $ | (0.02) | $ | (0.16) | |||||||||||
| December 31, | |||||||||||||||||
| 2025 | 2024 | 2023 | |||||||||||||||
| Stock options - service only condition | 8,646 | 9,163 | 9,430 | ||||||||||||||
Stock options - market and performance condition(1) | 4,289 | 6,962 | 7,826 | ||||||||||||||
| Restricted stock units | 20,939 | 17,858 | 10,065 | ||||||||||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 25, 2026 | Showing above |
| 2024 | Feb 25, 2025 | |
| 2023 | Feb 27, 2024 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.